The Montreal Heart Institute’s Research Center launched a COVID-19 clinical trial in Canada to assess whether short-term treatment could reduce the risk of pulmonary complications and related deaths. Titled COLCORONA, the clinical study is coordinated by the Montreal Health Innovations Coordinating Center (MHICC) and funded by the Government of Quebec as well as support by Pharmascience (the largest pharmaceutical employer in Quebec) and CGI, a leading information technology company.
COLCORONA will evaluate the phenomenon of major inflammatory storm present in adults suffering from severe complications related to COVID-19. The researchers hypothesized that the treatment could reduce the complications associated with COVID-19. The clinical study will involve the recruitment of approximately 6000 participants followed for 30 days. Initial results will be available a few days after study completion.
- Be tested positive for COVID-19
- Be 40 years and over
- Not hospitalized
- Be willing to take the drug or placebo daily for 30 days
- Be willing to participate in two follow-up calls by phone or video conference
Women who do not take contraceptives, those who are pregnant and those who are breastfeeding are not eligible for the clinical study.
About the Montreal Heart Institute
Founded in 1954, the Montreal Heart Institute constantly strives for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training and prevention. It is home to the largest cardiology research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in the country. The Institute is affiliated with the University of Montreal and has more than 2,000 employees, including 245 physicians and more than 85 researchers. The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization that is an integral part of the Montreal Heart Institute (ICM). The MHICC has a network of research collaborators in more than 4,500 clinical establishments over 30 countries. The MHICC has specific expertise in high quality clinical cost-efficient trials, precision medicine and the development of new indications for medicines.
Call to Action: Based in the Montreal area and interested in participating? Call 1-877-536-6837 or visit www.colcorona.orgSource: Globe Newswire